208 related articles for article (PubMed ID: 34468096)
1. [Residual risk of liver disease after hepatitis C virus eradication].
Ongaro M; Mathys P; Zampaglione L; Negro F
Rev Med Suisse; 2021 Sep; 17(748):1453-1456. PubMed ID: 34468096
[TBL] [Abstract][Full Text] [Related]
2. Risk stratification of hepatocellular carcinoma after hepatitis C virus eradication in patients with compensated advanced chronic liver disease in Japan.
Nakatsuka T; Tateishi R; Nakagomi R; Minami T; Koike K
J Hepatol; 2022 Aug; 77(2):569-571. PubMed ID: 35288188
[No Abstract] [Full Text] [Related]
3. Hepatocellular Carcinoma Risk Declines but Remains High Enough for Screening in the First 7 Years After Hepatitis C Virus Cure With Direct-Acting Antivirals in Patients With Cirrhosis or High Fibrosis-4 Score.
Kim NJ; Vutien P; Berry K; Ioannou GN
Gastroenterology; 2022 Oct; 163(4):1104-1106.e3. PubMed ID: 35777481
[No Abstract] [Full Text] [Related]
4. Should we continue surveillance for hepatocellular carcinoma and gastroesophageal varices in patients with cirrhosis and cured HCV infection?
Isfordink CJ; Maan R; de Man RA; van Erpecum KJ; van der Meer AJ
Eur J Intern Med; 2021 Dec; 94():6-14. PubMed ID: 34563447
[TBL] [Abstract][Full Text] [Related]
5. Predictive models for hepatocellular carcinoma development after sustained virological response in advanced hepatitis C.
Fraile-López M; Alvarez-Navascués C; González-Diéguez ML; Cadahía V; Chiminazzo V; Castaño A; Varela M; Rodríguez M
Gastroenterol Hepatol; 2023 Dec; 46(10):754-763. PubMed ID: 36716928
[TBL] [Abstract][Full Text] [Related]
6. Hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis: Who to screen and for how long?
Ahumada A; Rayón L; Usón C; Bañares R; Alonso Lopez S
World J Gastroenterol; 2021 Oct; 27(40):6737-6749. PubMed ID: 34790004
[TBL] [Abstract][Full Text] [Related]
7. Reply to: 'Risk stratification of hepatocellular carcinoma after hepatitis C virus eradication in patients with compensated advanced chronic liver disease in Japan'.
Semmler G; Mandorfer M
J Hepatol; 2022 Aug; 77(2):571-572. PubMed ID: 35526785
[No Abstract] [Full Text] [Related]
8. Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication.
Mueller PP; Chen Q; Ayer T; Nemutlu GS; Hajjar A; Bethea ED; Peters MLB; Lee BP; Janjua NZ; Kanwal F; Chhatwal J
J Hepatol; 2022 Jul; 77(1):55-62. PubMed ID: 35157959
[TBL] [Abstract][Full Text] [Related]
9. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
10. The risk of hepatocellular carcinoma after sustained virological response in patients treated with the new direct-acting antiviral drugs: should we be worry about it?
Blanco JR; Rivero-Juárez A
Expert Rev Anti Infect Ther; 2016 Nov; 14(11):993-996. PubMed ID: 27686837
[No Abstract] [Full Text] [Related]
11. Risk of hepatocellular carcinoma and fibrosis evolution in hepatitis C patients with severe fibrosis or cirrhosis treated with direct acting antiviral agents.
Hamoir C; Horsmans Y; Stärkel P; Dahlqvist G; Negrin Dastis S; Lanthier N
Acta Gastroenterol Belg; 2021; 84(1):25-32. PubMed ID: 33639690
[TBL] [Abstract][Full Text] [Related]
12. Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end.
Muzica CM; Stanciu C; Huiban L; Singeap AM; Sfarti C; Zenovia S; Cojocariu C; Trifan A
World J Gastroenterol; 2020 Nov; 26(43):6770-6781. PubMed ID: 33268960
[TBL] [Abstract][Full Text] [Related]
13. Liver Stiffness at the Time of Sustained Virological Response Predicts the Clinical Outcome in People Living With Human Immunodeficiency Virus and Hepatitis C Virus With Advanced Fibrosis Treated With Direct-acting Antivirals.
Corma-Gómez A; Macías J; Téllez F; Freyre-Carrillo C; Morano L; Rivero-Juárez A; Ríos MJ; Alados JC; Vera-Méndez FJ; Merchante N; Palacios R; Granados R; Merino D; De Los Santos I; Pineda JA
Clin Infect Dis; 2020 Dec; 71(9):2354-2362. PubMed ID: 31754695
[TBL] [Abstract][Full Text] [Related]
14. [Hepatitis C].
Moradpour D; Blum HE
Ther Umsch; 2004 Aug; 61(8):493-8. PubMed ID: 15457965
[TBL] [Abstract][Full Text] [Related]
15. Risk of hepatocellular carcinoma after hepatitis C virus cure.
Luna-Cuadros MA; Chen HW; Hanif H; Ali MJ; Khan MM; Lau DT
World J Gastroenterol; 2022 Jan; 28(1):96-107. PubMed ID: 35125821
[TBL] [Abstract][Full Text] [Related]
16. Unmet Needs in the Post-Direct-Acting Antiviral Era: Hepatocarcinogenesis After Hepatitis C Virus Eradication.
Przybyszewski EM; Chung RT
J Infect Dis; 2023 Sep; 228(Suppl 3):S226-S231. PubMed ID: 37703341
[TBL] [Abstract][Full Text] [Related]
17. Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearance.
Huang CF; Yeh ML; Huang CI; Lin YJ; Tsai PC; Lin ZY; Chan SY; Chen SC; Yang HI; Huang JF; Lu SN; Dai CY; Jen CL; Yuan Y; L'Italien G; Wang LY; Lee MH; Yu ML; Chuang WL; Chen CJ
Oncotarget; 2017 Jul; 8(27):43925-43933. PubMed ID: 28159934
[TBL] [Abstract][Full Text] [Related]
18. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis.
Mettke F; Schlevogt B; Deterding K; Wranke A; Smith A; Port K; Manns MP; Vogel A; Cornberg M; Wedemeyer H
Aliment Pharmacol Ther; 2018 Feb; 47(4):516-525. PubMed ID: 29205405
[TBL] [Abstract][Full Text] [Related]
19. The impact of treatment of hepatitis C with DAAs on the occurrence of HCC.
Roche B; Coilly A; Duclos-Vallee JC; Samuel D
Liver Int; 2018 Feb; 38 Suppl 1():139-145. PubMed ID: 29427487
[TBL] [Abstract][Full Text] [Related]
20. Residual risk of liver disease after hepatitis C virus eradication.
Negro F
J Hepatol; 2021 Apr; 74(4):952-963. PubMed ID: 33276027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
